Anuradha Sawant1, S Jayne Garland, Andrew A House, Tom J Overend. 1. Anuradha Sawant, DPT: PhD candidate, Graduate Program in Health and Rehabilitation Sciences, Physical Therapy Field, The University of Western Ontario, London, Ontario; Physiotherapist, London Health Sciences Centre, University Hospital Campus, 339 Windermere Road, London, Ontario.
Abstract
PURPOSE: Fatigue is one of the most frequent debilitating symptoms reported by people with end-stage renal disease (ESRD) on haemodialysis (HD) therapy. A wide range of underlying abnormalities, including skeletal muscle weakness, have been implicated as causes of this fatigue. Skeletal muscle weakness is well established in this population, and such muscle weakness is amenable to physical therapy treatment. The purpose of this review was to identify morphological, electrophysiological, and metabolic characteristics of skeletal muscles in people with ESRD/HD that may cause skeletal muscle weakness. METHOD: Electronic databases were searched for relevant literature from inception to March 2010. Inclusion criteria were English language; adult subjects with ESRD/HD; and the use of muscle biopsy, electromyography, and nuclear magnetic spectroscopy ((31)P-NMRS) techniques to evaluate muscle characteristics. RESULTS: In total, 38 studies were included. All studies of morphological characteristics reported type II fibre atrophy. Electrophysiological characteristics included both neuropathic and myopathic skeletal muscle changes. Studies of metabolic characteristics revealed higher cytosolic inorganic phosphate levels and reduced effective muscle mass. CONCLUSION: The results indicate an array of changes in the morphological, electrophysiological, and metabolic characteristics of skeletal muscle structure in people with ESRD/HD that may lead to muscle weakness.
PURPOSE: Fatigue is one of the most frequent debilitating symptoms reported by people with end-stage renal disease (ESRD) on haemodialysis (HD) therapy. A wide range of underlying abnormalities, including skeletal muscle weakness, have been implicated as causes of this fatigue. Skeletal muscle weakness is well established in this population, and such muscle weakness is amenable to physical therapy treatment. The purpose of this review was to identify morphological, electrophysiological, and metabolic characteristics of skeletal muscles in people with ESRD/HD that may cause skeletal muscle weakness. METHOD: Electronic databases were searched for relevant literature from inception to March 2010. Inclusion criteria were English language; adult subjects with ESRD/HD; and the use of muscle biopsy, electromyography, and nuclear magnetic spectroscopy ((31)P-NMRS) techniques to evaluate muscle characteristics. RESULTS: In total, 38 studies were included. All studies of morphological characteristics reported type II fibre atrophy. Electrophysiological characteristics included both neuropathic and myopathic skeletal muscle changes. Studies of metabolic characteristics revealed higher cytosolic inorganic phosphate levels and reduced effective muscle mass. CONCLUSION: The results indicate an array of changes in the morphological, electrophysiological, and metabolic characteristics of skeletal muscle structure in people with ESRD/HD that may lead to muscle weakness.
Authors: C H Thompson; G J Kemp; P R Barnes; B Rajagopalan; P Styles; D J Taylor; G K Radda Journal: Nephrol Dial Transplant Date: 1994 Impact factor: 5.992
Authors: Graham J Kemp; Alexander V Crowe; Hameed K I Anijeet; Qiyong Y Gong; William E Bimson; Simon P Frostick; J Michael Bone; Gordon M Bell; J Neil Roberts Journal: Nephrol Dial Transplant Date: 2004-03-05 Impact factor: 5.992
Authors: G I Mitrou; K P Poulianiti; Y Koutedakis; A Z Jamurtas; M D Maridaki; I Stefanidis; G K Sakkas; C Karatzaferi Journal: Hippokratia Date: 2017 Jan-Mar Impact factor: 0.471
Authors: Anuradha Sawant; Andrew A House; Bert M Chesworth; Denise M Connelly; Robert Lindsay; Joe Gati; Robert Bartha; Tom J Overend Journal: Physiol Rep Date: 2015-01-27
Authors: L Seefried; F Genest; N Luksche; M Schneider; G Fazeli; M Brandl; U Bahner; A A Heidland Journal: J Musculoskelet Neuronal Interact Date: 2017-12-01 Impact factor: 2.041